2021
DOI: 10.1016/j.anai.2020.12.014
|View full text |Cite
|
Sign up to set email alerts
|

Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 9 publications
(11 reference statements)
1
0
0
Order By: Relevance
“…Patients treated with it had lower NLR, dNLR, SII, PLR, and MLR at 48 h and delta values and higher absolute lymphocyte count values and survival rates. These findings are in agreement with results reported by other researchers for COVID-19 patients that received tocilizumab [ 38 ]. The positive effect of tocilizumab in other diseases seemed to be represented by a drop in NLR and neutrophil count [ 39 , 40 ].…”
Section: Discussionsupporting
confidence: 94%
“…Patients treated with it had lower NLR, dNLR, SII, PLR, and MLR at 48 h and delta values and higher absolute lymphocyte count values and survival rates. These findings are in agreement with results reported by other researchers for COVID-19 patients that received tocilizumab [ 38 ]. The positive effect of tocilizumab in other diseases seemed to be represented by a drop in NLR and neutrophil count [ 39 , 40 ].…”
Section: Discussionsupporting
confidence: 94%